Adaptive Biotechnologies (ADPT) Accounts Payables (2018 - 2026)

Adaptive Biotechnologies has disclosed Accounts Payables across 9 years of filings, most recently posting $5.2 million for Q2 2026.

• In Q2 2026, Accounts Payables fell 24.13% year-over-year to $5.2 million; the TTM figure through Jun 2026 stood at $5.2 million (down 24.13% YoY), while the FY2025 annual figure was $6.5 million, down 10.98% from the prior year.
• Accounts Payables came in at $5.2 million for Q2 2026 at Adaptive Biotechnologies, down from $9.6 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $12.2 million in Q1 2024 to a low of $2.7 million in Q2 2022.
• Average Accounts Payables over 5 years is $7.2 million, with a median of $7.1 million recorded in 2024.
• Year-over-year, Accounts Payables slumped 55.36% in 2022 and soared 236.88% in 2023.
• Over 5 years, Accounts Payables stood at $8.1 million in 2022, then dropped by 4.52% to $7.7 million in 2023, then declined by 5.88% to $7.3 million in 2024, then dropped by 10.98% to $6.5 million in 2025, then decreased by 18.96% to $5.2 million in 2026.
• Per Business Quant data, the three most recent Accounts Payables figures were $5.2 million in Q2 2026, $9.6 million in Q1 2026, and $6.5 million in Q4 2025.